# US 11,441,122 B2 · Regulatory T cell epitopes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,441,122 B2
- Document ID: US11441122B2
- Status: Granted
- Kind: B2
- Application number: 16/753,522
- Filed: 2018-10-05
- Published: 2020-10-01
- Granted: 2022-09-13
- Earliest claimed: 2017-10-05
- Assignees: EpiVax, Inc.; The United States of America, as Represented by the Secretary, Department of Health and Human Services Food and Drug Administration
- Applicants: EpiVax, Inc.; Food and Drug Adminstration
- Inventors: William Martin; Amy S. Rosenberg
- Web page: https://patentgrep.com/patent/US11441122B2

## CPC

- A61P 11/06: Antiasthmatics
- C12N 5/0637: {Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg}
- C07K 14/52: Cytokines; Lymphokines; Interferons
- C07K 14/70539: {MHC-molecules, e.g. HLA-molecules}
- C07K 14/745: Blood coagulation or fibrinolysis factors
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2319/00: Fusion polypeptide
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present is directed to compositions comprising regulatory T cell epitopes, wherein said epitopes comprise a polypeptide comprising at least a portion of SEQ NOS: 1-14, fragments and/or variants thereof, as well as methods of producing and using the same.

## Claims

### Claim 1

A method of inducing regulatory T-cells to suppress immune response in a subject comprising administrating to the subject a therapeutically effective amount of a T-cell epitope composition, wherein the T-cell epitope composition comprises one or more isolated T-cell epitope polypeptides, wherein at least one isolated T-cell epitope polypeptide consists of the amino acid sequence of SEQ ID NO: 1.

### Claim 2 (depends on 1)

The method of claim 1, wherein the T-cell epitope composition further comprises at least one isolated T-cell epitope polypeptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOS: 2-14.

### Claim 3 (depends on 1)

The method of claim 1, wherein the T-cell epitope composition further comprises an effective amount of one or more antigens and/or allergens.

### Claim 4 (depends on 1)

The method of claim 1, wherein the immune suppressive effect is mediated by natural regulatory T cells.

### Claim 5 (depends on 1)

The method of claim 1, wherein the immune suppressive effect is mediated by adaptive regulatory T-cells.

### Claim 6 (depends on 1)

The method of claim 1, wherein the T-cell epitope composition suppresses an effector T-cell response.

### Claim 7 (depends on 6)

The method of claim 6, wherein the T-cell epitope composition suppresses a cytokine secretion of effector T-cells.

### Claim 8 (depends on 1)

The method of claim 1, wherein the T-cell epitope composition suppresses a helper T-cell response.

### Claim 9 (depends on 1)

The method of claim 1, wherein the T-cell epitope composition suppresses a B-cell response.